Xuebing Li

Xuebing Li


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
CBCong Bo
Cong Bo
QWQiang Wu
Qiang Wu
HZHai Zhao
Hai Zhao
XLXuebing Li
Xuebing Li
QZQinghua Zhou
Qinghua Zhou
Background: Thymosin α1 (Tα1) is one of the most commonly used immunomodulators for metastatic non-small-cell lung cancer (NSCLC) patients in many countries. Despite the identification of the direct suppression on cancer cell proliferation, little is known about its effect on metastasis and metastasis-related signaling such as matrix metalloproteinases (MMPs) and programmed cell death ligand 1 (PD-L1). Materials and methods: NSCLC cells with distinguishing PD-L1 expression levels were treated with Tα1. siRNAs were used to knockdown PD-L1. Cell migration and invasion abilities were evaluated by wound-healing and transwell assays. The xenograft model by BALB/c nude mice was constructed to test the inhibitory effect of Tα1 on metastasis in vivo. The expression levels of metastasis-related signaling pathways and key molecules were assessed by Western blot (WB) and quantitative reverse transcriptase PCR (qRT-PCR). Results: Tα1 significantly suppressed cell migration and invasion in PD-L1 high-expressing H1299, NL9980, and L9981 cells but not in PD-L1 low-expressing A549 or SPC-A-1 cells. This difference was demonstrated by mouse model in vivo as well. Knocking down of PD-L1 significantly impaired the inhibition of cell migration and invasion caused by Tα1 treating in PD-L1 high-expressing cells. Besides, Tα1 inhibited the activation and translocation of STAT3 and the expression of MMP2 in PD-L1 high-expressing NSCLC cells. Moreover, the treatment of STAT3 activator colivelin could partly reverse the Tα1-induced MMP2 suppression and the migration phenotype. Conclusion: Tα1 significantly suppresses migration and invasion in PD-L1 high-expressing NSCLC cells compared with PD-L1 low-expressing NSCLC cells in vitro and in vivo, through the downregulation of STAT3–MMP2 signaling. These different responses to Tα1, together with the depiction of Tα1-induced signaling changes, suggest a potential benefit of Tα1 for PD-L1-positive NSCLC patients, enlightening the combination of Tα1 with target therapy or immune checkpoint inhibitors.

11 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
YFYaguang Fan
Yaguang Fan
YJYong Jiang
Yong Jiang
XLXin Li
Xin Li
XLXuebing Li
Xuebing Li
YLYang Li
Yang Li
YQYoulin Qiao
Youlin Qiao
Background: Little is known about trends in the lung cancer burden from the disease that can be attributed to occupational carcinogens in China. Methods: Data regarding the lung cancer burden that can be attributed to occupational carcinogens in China were extracted from the Global Burden of Disease (GBD) study in 2019. Joinpoint regression analysis and an age-period-cohort (APC) analysis were conducted to estimate the trend of lung cancer burden as a result of occupational carcinogens from 1990 to 2019. A Bayesian APC model was used to predict the disease burden until 2044. Results: The average annual percentage changes of age-standardized summary exposure values (SEVs) of occupational lung carcinogens, as well as the age-standardized population attributable fraction (PAF) of lung cancer due to occupational carcinogens, were 0.5% (95% confidence interval (CI): 0.4–0.5%) and 0.1% (95% CI: 0–0.2%), respectively. In addition, both the joinpoint regression analysis and APC analysis demonstrated significantly increased trends of age-standardized lung cancer mortality (ASMR) and age-standardized disability-adjusted life years (ASDR) as a result of occupational carcinogens. Asbestos and silica accounted for the two most important occupational lung carcinogens in China. The absolute burden is expected to increase, mainly due to population aging and the age-specific rate of illness. Conclusions: The lung cancer burden that could be attributed to occupational carcinogens significantly increased from 1990 to 2019 in China, and the absolute burden will continue to increase in the next 25 years.

13 November 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HPHongli Pan
Hongli Pan
ZPZhenhua Pan
Zhenhua Pan
FGFengjie Guo
Fengjie Guo
FMFanrong Meng
Fanrong Meng
LZLingling Zu
Lingling Zu
QZQinghua Zhou
Qinghua Zhou
MicroRNAs (miRNAs) have been reported to play significant roles in non-small-cell lung cancer (NSCLC). However, the roles of microRNA (miR)-1915-3p in NSCLC remain unclear. In this study, we aimed to explore the biological functions of miR-1915-3p in NSCLC. The expression of miR-1915-3p and SET nuclear proto-oncogene (SET) in NSCLC tissues were examined by quantitative real-time PCR (qRT-PCR). Migratory and invasive abilities of lung cancer were tested by wound healing and transwell invasion assay. The direct target genes of miR-1915-3p were measured by dual-luciferase reporter assay and western blot. Finally, the regulation between METTL3/YTHDF2/KLF4 axis and miR-1915-3p were evaluated by qRT-PCR, promoter reporter assay and chromatin immunoprecipitation (CHIP). miR-1915-3p was downregulated in NSCLC tissues and cell lines, and inversely associated with clinical TNM stage and overall survival. Functional assays showed that miR-1915-3p significantly suppressed migration, invasion and epithelial-mesenchymal transition (EMT) in NSCLC cells. Furthermore, miR-1915-3p directly bound to the 3′untranslated region (3′UTR) of SET and modulated the expression of SET. SET inhibition could recapitulate the inhibitory effects on cell migration, invasion and EMT of miR-1915-3p, and restoration of SET expression could abrogate these effects induced by miR-1915-3p through JNK/Jun and NF-κB signaling pathways. What’s more, miR-1915-3p expression was regulated by METTL3/YTHDF2 m6A axis through transcription factor KLF4. These findings demonstrate that miR-1915-3p function as a tumor suppressor by targeting SET and may have an anti-metastatic therapeutic potential for lung cancer treatment.

29 December 2023 in Life Sciences
Verified
Journal Article
Closed access
WAWenzhe An
Wenzhe An
QYQingqing Yang
Qingqing Yang
YXYunlan Xi
Yunlan Xi
HPHongli Pan
Hongli Pan
HHHua Huang
Hua Huang
XZXuexia Zhou
Xuexia Zhou

1 January 2017
Verified
Journal Article
Closed access
XLXuebing Li
Xuebing Li
XZXuexia Zhou
Xuexia Zhou
FHFeng Hua
Feng Hua
YFYaguang Fan
Yaguang Fan
LZLingling Zu
Lingling Zu
QZQinghua Zhou
Qinghua Zhou

20 November 2020
Verified
Journal Article
Open access
HPHongli Pan
Hongli Pan
XLXuebing Li
Xuebing Li
CCChen Chen
Chen Chen
YFYaguang Fan
Yaguang Fan
QZQinghua Zhou
Qinghua Zhou
M6A修饰是真核生物mRNA中最丰富的修饰之一,该过程受m6A甲基转移酶和去甲基化酶的共同调控。m6A修饰后的RNA能够被m6A识别蛋白特异性识别并结合,进而介导RNA的剪接、成熟、出核、降解和翻译等。目前国内外对于m6A修饰及其相关蛋白如何参与非小细胞肺癌发生发展的研究,主要集中于细胞恶性增殖、迁移、侵袭、转移和耐药等方面。m6A修饰相关蛋白在肺癌组织标本和血液循环肿瘤细胞(circulating tumor cell, CTC)中表达异常,有望成为肺癌诊断和预后判断的潜在分子标志物。本文围绕m6A修饰相关蛋白的组成、作用方式、在非小细胞肺癌恶性进展中的生物学功能,以及针对m6A修饰的靶向治疗等方面的研究进展进行综述,旨在为非小细胞肺癌的早期临床诊断和靶向药物的开发提供新思路。